Lenalidomide news

All news on Lenalidomide (also known as Revlimid): plants, production capacities, investments and involved companies.

17 February 2026

Genmab Releases 2025 Annual Report

The report highlights 2025 achievements, financials, and 2026 outlook, including revenue growth, strategic acquisitions, and regulatory approvals.
16 January 2026

Genmab Reports Phase 3 Trial Results for Epcoritamab in Relapsed/Refractory DLBCL

Epcoritamab shows improved progression-free survival in Phase 3 trial for R/R DLBCL. Safety profile consistent. Further analysis and regulatory discussions planned.
14 January 2026

Johnson & Johnson's TECVAYLI® Shows Improved Survival in Multiple Myeloma Patients

TECVAYLI® monotherapy reduces disease progression and death risk in multiple myeloma patients refractory to anti-CD38 and lenalidomide, showing superior survival benefits.
22 December 2025

Roche's Lunsumio VELO Approved by FDA for Subcutaneous Use in Follicular Lymphoma

Lunsumio VELO cuts treatment time to one minute for relapsed follicular lymphoma, offering outpatient care with a manageable safety profile.
7 December 2025

Genmab's Phase 3 Trial Shows EPKINLY + R2 Benefits in Relapsed Follicular Lymphoma

EPKINLY + R2 reduces disease progression risk by 79% in relapsed follicular lymphoma, with a 95% response rate. FDA-approved, it offers a new second-line treatment option.
18 November 2025

Genmab's EPKINLY Combination Approved by FDA for Relapsed Follicular Lymphoma

EPKINLY + R² shows superior progression-free survival and response rates in Phase 3 trial for relapsed follicular lymphoma, with a consistent safety profile.

Who will be producing Lenalidomide in the future?

Find out with chemXplore Analytics